Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1911881 | 0.76 | — | — | |
| SCHEMBL29741837 | 0.76 | — | — | |
| Trimethylammonium SCHEMBL27685780 | 0.74 | CA2 (0.46) | CDK5CDK1CCNB1CCNA2CCNE1 | |
| SCHEMBL18469869 | 0.71 | — | — | |
| SCHEMBL19679369 | 0.71 | CDK5 (0.41) | CDK5CDK1CCNB1CCNA2CCNE1 | |
| SCHEMBL17591565 | 0.71 | JAK2 (0.43) | CDK5CDK1CCNB1CCNA2CCNE1 | |
| SCHEMBL10188164 | 0.71 | EGFR (0.49) | CDK5CDK1CCNB1CCNA2CCNE1 | |
| SCHEMBL30579411 | 0.71 | JAK2 (0.43) | CDK5CDK1CCNB1CCNA2CCNE1 | |
| SCHEMBL30781995 | 0.71 | SCN9A (0.50) | CDK5CDK1CCNB1CCNA2CCNE1 | |
| SCHEMBL31639080 | 0.69 | MAP4K4 (0.44) | CDK5CDK1CCNB1CCNA2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | CDK5 1186/4885CDK1 345/4885CCNB1 229/4885 |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | CDK5 1186/4885CDK1 345/4885CCNB1 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.